SEARCH

Current Edition

Alzheimer

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …

Continue Reading →
CRISPR

Vertex aligns with another CRISPR gene editing startup

Mammoth’s evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to …

Continue Reading →
CRISPR

Lilly joins RNA editing race with ProQR deal

Much of the attention in the genetic editing world in recent years has been on CRISPR and the “genetic scissors” that allow researchers to make …

Continue Reading →
CRISPR

CRISPR-Cas9 Knockout Screening Using Primary Human Cells in Drug Discovery

While significant progress has been made carrying out CRISPR screens in immortalised cell lines, a more physiological and clinically relevant alternative is human primary cells, …

Continue Reading →
clinical

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics’ lead candidate, spurring a double-digit drop in the Swiss biotech’s stock value by Thursday morning. …

Continue Reading →